(Q40287066)

19 September 2017

title

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study (English)

1 reference

19 September 2017

1 reference

S Altrichter

5

0 references

Frank Siebenhaar

object named as

F Siebenhaar

6

0 references

Torsten Zuberbier

7

object named as

T Zuberbier

1 reference

19 September 2017

8

M Maurer

1 reference

19 September 2017

K Krause

1

1 reference

19 September 2017

K Weller

2

1 reference

19 September 2017

R Stefaniak

3

1 reference

19 September 2017

H Wittkowski

4

1 reference

19 September 2017

publication date

15 May 2012

1 reference

19 September 2017

1 reference

19 September 2017

volume

67

1 reference

19 September 2017

issue

7

1 reference

19 September 2017

page(s)

943-950

1 reference

The Schnitzler syndrome. Four new cases and review of the literature

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

21 January 2018

The Schnitzler syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Prompt response of refractory Schnitzler syndrome to treatment with anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Dysfunctional inflammasome in Schnitzler's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

The inflammasome: first line of the immune response to cell stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

The inflammasome: a danger sensing complex triggering innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Proinflammatory S100 proteins in arthritis and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2012.02843.X

10.1111/J.1398-9995.2012.02843.X

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference